HOME >> MEDICINE >> NEWS
Fertility worries common in young breast cancer survivors

BOSTON A survey of young breast cancer survivors found that more than half likely overestimated their risk for developing treatment related infertility, according to researchers from the Dana-Farber Cancer Institute.

The study, described in an oral presentation December 5 at the San Antonio Breast Cancer Symposium, is the largest to date that addresses fertility and menopausal concerns among young women with breast cancer.

The results serve as a wakeup call for health care providers, said Ann H. Partridge, MD, MPH, because "we don't have a great system for educating these women and showing them data even if incomplete about these questions and advising them on what they can consider to attempt to preserve fertility."

According to the result of the Web-based survey, 72 percent of the women said they had discussed fertility issues with their doctor and 17 percent had talked with a fertility specialist. Still, one-quarter of the women felt their unease about fertility was not adequately addressed.

As to whether a woman will retain her fertility, Partridge said the effects of older treatments are fairly well known, but there is less information on newer chemotherapy agents and ways of administering the chemotherapy. When asked to estimate their odds, more than half of women under 30 thought they had a 40 percent or greater chance of becoming infertile, when in fact research have revealed that very few women in this very young age group go through menopause with standard treatment, some studies showing a zero percent incidence in these patients, said Partridge. "Their risk perceptions are likely grossly exaggerated; there is room for education here."

Partridge, of the Breast Oncology Center at Dana-Farber, headed the study; senior author is Eric Winer, MD, the Center's director. The survey's 657 respondents were members of the Young Survival Coalition (YSC) an Internet-based advocacy group for young women with breast cancer. The mean age
'"/>

Contact: Janet Haley Dubow
janet_haley@dfci.harvard.edu
617-632-5665
Dana-Farber Cancer Institute
5-Dec-2003


Page: 1 2

Related medicine news :

1. Fertility herbal supplement sprouts promising results in Stanford pilot study
2. UF Researcher Explores Complex Relationship Between Smoking And Fertility
3. Cost, availability of insurance and drugs top health care worries
4. Why asthma sufferers struggle with the common cold
5. Use of potentially inappropriate medications among elderly common in some European countries
6. Adverse drug events in nursing homes are far more common than previously identified
7. Herbal extract as effective as commonly prescribed anti-depressant
8. Clinicians report missing patient information is common
9. Depression caused by common treatment for hepatitis C may affect outcome
10. FDA approves Pfizers Lyrica for the treatment of the two most common forms of neuropathic pain
11. Study determines commonly used contrast agent safe for universal use in CT

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Fertility worries common young breast cancer survivors

(Date:7/30/2014)... July 30, 2014 Hospitals continually ... quality of care that their practitioners provide. During ... Andrew Rowe, discussed the importance of establishing effective ... physician performance and quality of care. , ... evaluation, Mr. Rowe elaborated on setting performance expectations, ...
(Date:7/30/2014)... Frozen shoulder (Adhesive capsulitis) affects 10-20 percent ... this nasty condition which occurs most frequently in people between ... to two and half years if not treated. , Adhesive ... good reason: it can render your shoulder so stiff, it's ... you aren't in too much pain to get dressed in ...
(Date:7/30/2014)... (HealthDay News) --,Although the vast majority of kids with ... wired very differently from children who have trouble processing ... disorders (SPD) can be overly sensitive to sound, sight ... and show a lack of concentration. Complicating matters, ... others. Some have trouble tolerating loud noises, like a ...
(Date:7/30/2014)... India (PRWEB) July 30, 2014 On ... Campaign, and the Indian Institute of Public Health, Gandhinagar ... Microfinance in India, Volume II: The Way Forward .” ... Asia Conference on Policies and Practices to Improve Nutrition ... the "Indian Father of the Green Revolution" and chair ...
(Date:7/30/2014)... 2014 The North America aviation actuator ... 2019. North America is expected to be the fastest ... a CAGR of 5.60%. , The commercial aircraft ... which will assume prominence in the years to come. ... the sector has regained quickly, and the industry has ...
Breaking Medicine News(10 mins):Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 2Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 2Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 4Health News:North America Aviation Actuation System Market is Expected to Reach $1781.02 million in 2019 - New Report by MicroMarket Monitor 2Health News:North America Aviation Actuation System Market is Expected to Reach $1781.02 million in 2019 - New Report by MicroMarket Monitor 3Health News:North America Aviation Actuation System Market is Expected to Reach $1781.02 million in 2019 - New Report by MicroMarket Monitor 4
(Date:7/30/2014)... -- Stryker brand ambassadors Fred Funk and Hal ... Tour event near Minneapolis, MN , which begins ... Stryker is the official joint replacement products company of the PGA ... st through Sunday, August 3 rd , fans will be ... destination located in the Pioneer Press Expo tent located near the ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... and SAN DIEGO , July ... ARNA ) announced today that an article based ... of lorcaserin entitled, "Early Weight Loss While on Lorcaserin, Diet, ... was recently published in the online issue of Obesity ... The objective of these analyses was to identify whether there ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
Cached News: